Looker Benjamin
Insider CIK 1859509 · ESPR General Counsel · TRIL General Counsel
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ESPR Esperion Therapeutics, Inc | D To issuer deriv | 2026-07-13 | 2026-07-13 | 201,000 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | D To issuer deriv | 2026-07-13 | 2026-07-13 | 150,000 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | D To issuer deriv | 2026-07-13 | 2026-07-13 | 269,230 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | D To issuer | 2026-07-13 | 2026-07-13 | 667,524 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2026-06-17 | 2026-06-18 | 11,824 | $3.16 | $37.4K | 667,524 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2026-03-17 | 2026-03-18 | 5,708 | $2.70 | $15.4K | 679,348 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2026-03-13 | 2026-03-16 | 269,230 | — | $0 | 269,230 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award | 2026-03-13 | 2026-03-16 | 300,840 | — | $0 | 685,056 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2026-01-20 | 2026-01-21 | 1,689 | $2.88 | $4.9K | 384,216 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2025-12-17 | 2025-12-18 | 6,517 | $3.67 | $23.9K | 385,905 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2025-10-17 | 2025-10-20 | 1,248 | $2.62 | $3.3K | 392,422 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2025-09-17 | 2025-09-18 | 6,267 | $2.80 | $17.5K | 393,670 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2025-07-17 | 2025-07-18 | 1,304 | $1.13 | $1.5K | 399,937 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2025-06-17 | 2025-06-18 | 6,422 | $1.15 | $7.4K | 401,241 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2025-03-14 | 2025-03-17 | 201,000 | — | $0 | 201,000 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award | 2025-03-14 | 2025-03-17 | 224,000 | — | $0 | 407,663 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2024-03-14 | 2024-03-15 | 150,000 | — | $0 | 150,000 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award | 2024-03-14 | 2024-03-15 | 100,000 | — | $0 | 183,663 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2023-04-19 | 2023-04-20 | 1,290 | $1.27 | $1.6K | 83,663 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2023-03-14 | 2023-03-15 | 86,900 | — | $0 | 86,900 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award | 2023-03-14 | 2023-03-15 | 20,500 | — | $0 | 84,953 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2023-01-18 | 2023-01-19 | 6,347 | $7.00 | $44.4K | 64,453 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2022-06-07 | 2022-06-09 | 52,000 | — | $0 | 52,000 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award deriv | 2022-01-27 | 2022-01-28 | 100,450 | — | $0 | 100,450 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | A Award | 2022-01-27 | 2022-01-28 | 70,800 | — | $0 | 70,800 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | D To issuer deriv | 2021-11-17 | 2021-11-19 | 190,000 | — | $0 | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | A Award deriv | 2021-05-03 | 2021-05-05 | 190,000 | — | $0 | 190,000 | SEC↗ |